Palivizumab (Synagis) for prevention of respiratory illness in children.
Respiratory syncytial virus commonly causes infections that are of little consequence to most of us. However, for the newborn and at-risk older children, infection can mean serious, even life-threatening respiratory illness affecting pulmonary development and resulting in chronic chest disease. Palivizumab is a new medicine of the high-tech era designed specifically to prevent such problems. Its managed entry into clinical practice sets a challenge for health authorities across the country in ensuring most cost-effective delivery of health care.